by EMA Approval | 30 August 2024 | Lung Cancer, Urogenital
The European Commission has approved two new cancer treatments: enfortumab vedotin in combination with pembrolizumab for urothelial cancer and amivantamab-vmjw in combination with chemotherapy for non-small cell lung cancer (NSCLC). These approvals mark significant...
by EMA Approval | 12 July 2024 | Urogenital, Women's Cancers
The European Union has recommended new treatment options for patients with primary advanced or recurrent endometrial cancer and metastatic urothelial carcinoma. Durvalumab and Olaparib have been endorsed for endometrial cancer based on positive trial results, while...
by Deborah Mukherji | 3 July 2024 | Urogenital
Clinical trials investigating various drugs in patients with metastatic hormone-sensitive or castration-resistant prostate cancer have revealed significant benefits. While research is ongoing to shed light on issues such as sequencing, treatment de-escalation and...
by Swiss Approval | 24 June 2024 | Urogenital
In recent developments within the field of oncology, several new treatment options have received approval, offering fresh hope for patients battling various forms of cancer. These approvals highlight the advancements in targeted therapies and the ongoing commitment to...
by Alison Birtle | 5 June 2024 | Urogenital
Enfortumab vedotin (EV) plus pembrolizumab has recently been established as the new first-line treatment standard in advanced urothelial carcinoma. Clear guidance on how to manage the typical side effects of this regimen is necessary to allow for the successful use of...
